Flagship record · Retatrutide

Emerging pharmacotherapies for obesity: A systematic review.

systematic review meta analysisreview level evidenceclass level evidence

Scientific attribution

The systematic review evaluates a broader emerging anti-obesity pharmacotherapy class rather than retatrutide as a single primary intervention.

PMID: 39952695
DOI: 10.1124/pharmrev.123.001045
Sample size: Not captured in the structured review record
Population / model: However, categories of emerging pharmacotherapies generate hope to reduce obesity rates.

Intervention / comparator

This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the effect of novel weight loss pharmacotherapies, compared to placebo/control or US Food and Drug Administration-approved weight loss medication, through searching Medline, Embase, and ClinicalTrials.gov (2012-2024).

Outcomes

The history of antiobesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the prevailing conviction that excess body weight signifies a lack of willpower.
This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the effect of novel weight loss pharmacotherapies, compared to placebo/control or US Food and Drug Administration-approved weight loss medication, through searching Medline, Embase, and ClinicalTrials.gov (2012-2024).
Completed phase 2 trials on incretin-based therapies showed a mean percent weight loss of 7.4% to 24.2%.

Key findings

The obesity drug pipeline is expanding rapidly, with the most promising results reported with incretin analogs.

Limitations

Moreover, long-term follow-up data on the safety and efficacy of weight maintenance with novel obesity pharmacotherapies, along with studies focused on underrepresented populations, cost-effectiveness assessments, and drug availability, are needed to bridge the care gap for patients with obesity.

Contradiction / qualification signals

However, categories of emerging pharmacotherapies generate hope to reduce obesity rates.
However, emerging alternatives of novel agents and combinations populate the current obesity therapeutic pipeline.

Review status

This research library contains structured AI-assisted scientific review. AI-assisted review is not accountable human scientific approval. Inclusion here does not constitute publication approval, clinical guidance, efficacy proof, or automatic promotion of a scientific conclusion.

Loading research intelligence

Preparing the structured Flagship evidence library.

Emerging pharmacotherapies for obesity: A systematic review.

systematic review meta analysisreview level evidenceclass level evidence

Scientific attribution

The systematic review evaluates a broader emerging anti-obesity pharmacotherapy class rather than retatrutide as a single primary intervention.

PMID

39952695

DOI

10.1124/pharmrev.123.001045

Sample size

Not captured in the structured review record

Population / model

However, categories of emerging pharmacotherapies generate hope to reduce obesity rates.

Intervention / comparator

This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the effect of novel weight loss pharmacotherapies, compared to placebo/control or US Food and Drug Administration-approved weight loss medication, through searching Medline, Embase, and ClinicalTrials.gov (2012-2024).

Outcomes

The history of antiobesity pharmacotherapies is marked by disappointments, often entangled with societal pressure promoting weight loss and the prevailing conviction that excess body weight signifies a lack of willpower.
This systematic review of phase 2 and phase 3 trials in adults with overweight/obesity investigates the effect of novel weight loss pharmacotherapies, compared to placebo/control or US Food and Drug Administration-approved weight loss medication, through searching Medline, Embase, and ClinicalTrials.gov (2012-2024).
Completed phase 2 trials on incretin-based therapies showed a mean percent weight loss of 7.4% to 24.2%.

Key findings

The obesity drug pipeline is expanding rapidly, with the most promising results reported with incretin analogs.

Limitations

Moreover, long-term follow-up data on the safety and efficacy of weight maintenance with novel obesity pharmacotherapies, along with studies focused on underrepresented populations, cost-effectiveness assessments, and drug availability, are needed to bridge the care gap for patients with obesity.

Contradiction / qualification signals

However, categories of emerging pharmacotherapies generate hope to reduce obesity rates.
However, emerging alternatives of novel agents and combinations populate the current obesity therapeutic pipeline.